Trials / Unknown
UnknownNCT04261270
A Randomized,Open,Controlled Clinical Study to Evaluate the Efficacy of ASC09F and Ritonavir for 2019-nCoV Pneumonia
A Randomized,Open,Controlled Small Sample Clinical Study to Evaluate the Efficacy and Safety of ASC09/Ritonavir Compound Tablets and Ritonavir for 2019-nCoV Pneumonia
- Status
- Unknown
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- Sponsor
- Tongji Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Not accepted
Summary
Based on oseltamivir treatment, evaluate the efficacy and safety of ASC09/ritonavir compound tablets(ASC09F) or ritonavir tablets for 2019-nCoV infection patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ASC09F+Oseltamivir | ASC09F tablets:one tablet(400mg/tablet)twice a day for 14 days;Oseltamivir tablet:75mg,once a day |
| DRUG | Ritonavir+Oseltamivir | Ritonavir tablet:three tablets(100mg/tablet)twice a day for 14 days;Oseltamivir tablet:75mg,once a day |
| DRUG | Oseltamivir | 75mg ,once a day |
Timeline
- Start date
- 2020-02-01
- Primary completion
- 2020-05-01
- Completion
- 2020-07-01
- First posted
- 2020-02-07
- Last updated
- 2020-03-17
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04261270. Inclusion in this directory is not an endorsement.